Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
The study was closed to enrollment on 14 Jan 2011 and terminated secondary to excessive screen failure rate and for business reasons associated with Pfizer's business decision to stop development of the figitumumab compound. Safety concerns did not contribute to the decision to terminate this clinical trial.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically or cytologically confirmed advanced solid tumors relapsed or refractory to standard therapy or for whom no standard therapy exists.
ECOG Performance Status of 0 or 1;
Total IGF-1 level ≥100 ng/ml;
ECOG Performance Status of 0 or 1
Adequate bone marrow, renal, and hepatic function
You may not be if
Concurrent treatment with any antitumor agents with the exception of LHRH agnosits for prostate cancer patients
Treatment with any other investigational therapy within 4 weeks prior to study treatment
Major surgery within 4 weeks of study treatment
Prior treatment that may increase the risk of cardiac complications
Ongoing cardiac dysrhythmias of NCI CTCAE Grade 2 or greater
Significant active cardiac disease, including hypertension that cannot be controlled by medications
Greater than three (3) prior lines of cytotoxic therapy;
